

Michael A Linden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5952695/publications.pdf>

Version: 2024-02-01

84
papers

1,300
citations

471509

17
h-index

395702

33
g-index

84
all docs

84
docs citations

84
times ranked

2412
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , 2017, 102, 865-873.	3.5	206
2	Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. <i>Journal of Clinical Investigation</i> , 2004, 113, 1763-1773.	8.2	84
3	Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. <i>Blood</i> , 2003, 102, 2581-2592.	1.4	71
4	Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. <i>Journal of Clinical Investigation</i> , 2004, 113, 1763-1773.	8.2	70
5	Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1140-1150.	4.1	68
6	Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 669-675.	2.0	54
7	Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. <i>Blood</i> , 2004, 103, 2779-2786.	1.4	46
8	Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020, 80, 458-470.	0.9	46
9	Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. <i>Leukemia</i> , 2013, 27, 2075-2077.	7.2	45
10	<i>Sleeping Beauty</i> Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. <i>Cancer Research</i> , 2017, 77, 6576-6588.	0.9	40
11	Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice. <i>Hepatology</i> , 2018, 67, 924-939.	7.3	36
12	Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1276-1280.	2.5	30
13	Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. <i>Bone Marrow Transplantation</i> , 2013, 48, 1415-1420.	2.4	29
14	Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. <i>Laboratory Medicine</i> , 2018, 49, 134-139.	1.2	27
15	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
16	Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma. <i>Journal of Cancer</i> , 2014, 5, 720-727.	2.5	20
17	Hematopoietic Cell Transplantation for Mantle Cell Lymphoma: Predictive Value of Pretransplant Positron Emission Tomography/Computed Tomography and Bone Marrow Evaluations for Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 114-121.	0.4	20
18	Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 1222.	7.1	19

#	ARTICLE	IF	CITATIONS
19	Green Neutrophilic Inclusions are Frequently Associated With Liver Injury and May Portend Short-Term Mortality in Critically Ill Patients. <i>Laboratory Medicine</i> , 2017, 48, 18-23.	1.2	18
20	Variability in the Laboratory Measurement of Cytokines. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1230-1233.	2.5	18
21	Factor V Leiden and hepatic artery thrombosis after liver transplantation. <i>Clinical Transplantation</i> , 2006, 20, 132-135.	1.6	17
22	Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1931-1940.	1.3	17
23	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. <i>American Journal of Hematology</i> , 2017, 92, 1032-1036.	4.1	17
24	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq0 0 0 rgBT /Overlo	2.8	17
25	Bortezomib Resistance Can Be Reversed by Induced Expression of Plasma Cell Maturation Markers in a Mouse In Vitro Model of Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e77608.	2.5	17
26	Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. <i>Oncotarget</i> , 2016, 7, 76047-76061.	1.8	17
27	Genetic Signature of Histiocytic Sarcoma Revealed by a Sleeping Beauty Transposon Genetic Screen in Mice. <i>PLoS ONE</i> , 2014, 9, e97280.	2.5	16
28	ZBTB20 regulates WNT/CTNNB1 signalling pathway by suppressing PPARG during hepatocellular carcinoma tumourigenesis. <i>JHEP Reports</i> , 2021, 3, 100223.	4.9	13
29	An Innovative Method for Obtaining Consistent Images and Quantification of Histochemically Stained Specimens. <i>Journal of Histochemistry and Cytochemistry</i> , 2015, 63, 233-243.	2.5	10
30	Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. <i>Leukemia and Lymphoma</i> , 2017, 58, 1702-1710.	1.3	10
31	Quality and Adequacy of Bone Marrow Samples Obtained by the 2-Needle Technique: The Minnesota Experience. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 860-862.	2.5	9
32	ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-XL transgenic mice. <i>Leukemia Research</i> , 2005, 29, 435-444.	0.8	8
33	Early Diagnosis of Intravascular Large B-Cell Lymphoma: Clues From Routine Blood Smear Morphologic Findings. <i>Laboratory Medicine</i> , 2014, 45, 248-252.	1.2	8
34	Hematopoietic and Lymphoid Tissues. , 2012, , 309-338.		7
35	Perigestational Dietary Folic Acid Deficiency Protects Against Medulloblastoma Formation in a Mouse Model of Nevoid Basal Cell Carcinoma Syndrome. <i>Nutrition and Cancer</i> , 2013, 65, 857-865.	2.0	7
36	Unusual extramedullary hematopoietic neoplasms in lymph nodes. <i>Human Pathology</i> , 2017, 62, 13-22.	2.0	7

#	ARTICLE	IF	CITATIONS
37	VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months. <i>American Journal of Clinical Pathology</i> , 2020, 153, 221-228.	0.7	7
38	Induced \hat{I}° Receptor Editing Shows No Allelic Preference in a Mouse Pre-B Cell Line. <i>Journal of Immunology</i> , 2000, 165, 7058-7063.	0.8	6
39	B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry. <i>Human Pathology</i> , 2017, 61, 140-147.	2.0	6
40	CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up. <i>American Journal of Clinical Pathology</i> , 2019, 152, 471-478.	0.7	6
41	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
42	Interlaboratory Agreement of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serologic Assays in the Expedited College of American Pathologists Proficiency Testing Program. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 536-542.	2.5	6
43	Castleman disease: A single-center case series. <i>International Journal of Surgery Case Reports</i> , 2021, 80, 105650.	0.6	6
44	Myeloid Sarcoma Expressing Keratins and Mimicking Carcinoma—Case Report and Literature Review. <i>Laboratory Medicine</i> , 2022, 53, 100-106.	1.2	6
45	Parenchymal infiltration and lymphoma-associated membranoproliferative pattern of glomerular injury: an unusual presentation of mantle cell lymphoma. <i>Clinical Nephrology</i> , 2015, 84 (2015), 173-180.	0.7	6
46	Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction. <i>American Journal of Hematology</i> , 2013, 88, 329-332.	4.1	5
47	Abnormal immunophenotype of the T-cell receptor beta Chain in follicular-helper T cells of angioimmunoblastic T-cell lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2015, 88, 190-193.	1.5	5
48	Anaplastic mast cell sarcoma: a unique pathologic entity in mastocytosis. <i>Leukemia and Lymphoma</i> , 2017, 58, 1515-1517.	1.3	5
49	Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. <i>Experimental Hematology</i> , 2012, 40, 216-227.	0.4	4
50	Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course. <i>American Journal of Clinical Pathology</i> , 2016, 145, 459-466.	0.7	4
51	Lines of Zahn in the Splenic Vein. <i>Thrombosis and Haemostasis</i> , 2018, 118, 957-958.	3.4	4
52	Utility of Flow Cytometry to Classify Abnormal Plasma Cell Populations in Marrow Samples Collected from Patients with Putative Plasma Cell Neoplasms. <i>Open Journal of Blood Diseases</i> , 2012, 02, 39-45.	0.1	4
53	Long-Term Variability in Immunofluorescence Titer of Antibodies to Nuclear Antigens Observed in Clinical Laboratory Proficiency Testing Surveys. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 937-942.	2.5	4
54	Acute Appendicitis in a Man Undergoing Therapy for Mantle Cell Lymphoma. <i>Case Reports in Hematology</i> , 2012, 2012, 1-4.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. <i>Leukemia and Lymphoma</i> , 2013, 54, 174-176.	1.3	3
56	Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual diseaseâ€”negative first complete remission. <i>American Journal of Hematology</i> , 2018, 93, E381-E383.	4.1	3
57	Sarcoid-like Histiocytic Proliferations in Patients With Lymphoma Can Be FDG-avid Concerning for Refractory or Recurrent Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e597-e601.	0.4	3
58	Indolent B-Lineage Precursor Populations Identified by Flow Cytometry and Immunohistochemistry in Benign Lymph Nodes. <i>American Journal of Clinical Pathology</i> , 2021, , .	0.7	3
59	Performance of perpendicular drop versus tangent skimming gating of M-protein in proficiency testing challenges. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e19-e22.	2.3	3
60	Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by alloâ€”inactivation and ILC2â€”mediated tissue repair. <i>American Journal of Transplantation</i> , 2021, , .	4.7	3
61	Burkitt Lymphoma in Pregnancy: Two Cases of Successful Treatment and Continued Fertility; With a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, e10-e14.	0.4	2
62	How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. <i>American Journal of Hematology</i> , 2013, 88, 826-827.	4.1	2
63	Case study interpretationâ€”New Orleans: Case 4. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84, 350-353.	1.5	2
64	Genomics of clonal evolution in a case of essential thrombocythemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 497-500.	1.3	2
65	Autologous and Allogeneic Donor Transplantation for Mantle Cell Lymphoma in Rituximab Era: Impact of Pre-Transplant Burden On Survival.. <i>Blood</i> , 2012, 120, 3092-3092.	1.4	2
66	Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 336-342.	2.5	2
67	Patients without cutaneous Tâ€”cell lymphoma frequently harbor <scp>CD4</scp> Tâ€”lymphocytes that lack <scp>CD26</scp> and/or <scp>CD7</scp>. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 412-414.	1.5	2
68	Use of B-Type Natriuretic Peptide Testing in a Community Teaching Hospital 4 Years After Implementation and Agreement of Results with Discharge Diagnoses. <i>Clinical Chemistry</i> , 2006, 52, 767-768.	3.2	1
69	Standardization of Minimal Residual Disease Testing in Multiple Myeloma. <i>journal of applied laboratory medicine, The</i> , 2017, 2, 118-122.	1.3	1
70	Adult Langerhans histiocytosis with rare BRAF mutation complicated by massive pulmonary embolism. <i>Thrombosis Research</i> , 2020, 193, 207-210.	1.7	1
71	Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome. <i>Leukemia Research</i> , 2020, 95, 106404.	0.8	1
72	Romiplostim Improves Platelet Recovery after UCB Transplant. <i>Blood</i> , 2019, 134, 1979-1979.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Role of Flow Cytometry in Plasma Cell Neoplasms. , 2016, , 101-122.		1
74	Crystallizing Immunoglobulin Presenting as Polychromatic Crystalline Keratopathy: An Unusual Clinical Presentation of Monoclonal Gammopathy of Undetermined Significance (MGUS). Laboratory Medicine, 2013, 44, 344-347.	1.2	0
75	Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency. Leukemia and Lymphoma, 2014, 55, 220-222.	1.3	0
76	In Reply. Archives of Pathology and Laboratory Medicine, 2015, 139, 846-847.	2.5	0
77	Encapsulated relapsed FLT3+AML (myeloid sarcoma) and <sc>H</sc> cell adenoma presenting in composite: Unlikely partners. American Journal of Hematology, 2016, 91, E505-E506.	4.1	0
78	CLINICAL CHALLENGE. Journal of Zoo and Wildlife Medicine, 2016, 47, 948-951.	0.6	0
79	Patient and External Quality Assessment Samples Demonstrate Similar Bias Between Manufacturers in Titer of Antibodies to Nuclear Antigens: Implications for Commutability. Archives of Pathology and Laboratory Medicine, 2021, 145, 919-920.	2.5	0
80	Targeted Overexpression of Mutant Activated N-ras Leads to Aberrant Plasma Cell Biology.. Blood, 2004, 104, 1416-1416.	1.4	0
81	Bortezomib Is Highly Effective For Pure Red Cell Aplasia After ABO-Incompatible Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 5495-5495.	1.4	0
82	Standardized Synoptic Reports for Plasma Cell Neoplasms: Integration of Laboratory and Clinical Data. , 2016, , 143-149.		0
83	The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis. Blood, 2016, 128, 2842-2842.	1.4	0
84	Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF). Blood, 2020, 136, 40-41.	1.4	0